Another JAK inhibitor can now be prescribed at general hospitals in Korea.

According to industry sources, Gilead's Jyseleca (filgotinib) has passed the drug committee (DC) review of major national hospitals and medical institutions like Seoul Asan Medical Center and Hanyang University Hospital.

After the drug was approved for reimbursement in November last year, its company is now starting to compete for prescriptions in earnest.

Jyseleca was first approved with reimbursement as a treatment for rheumatoid arthritis and moderate-to-severe active ulcerative colitis. Patients eligible for reimbursement are those with either of the conditions and do not respond adequately to o